WO2015105290A1 - 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 - Google Patents
신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 Download PDFInfo
- Publication number
- WO2015105290A1 WO2015105290A1 PCT/KR2014/012726 KR2014012726W WO2015105290A1 WO 2015105290 A1 WO2015105290 A1 WO 2015105290A1 KR 2014012726 W KR2014012726 W KR 2014012726W WO 2015105290 A1 WO2015105290 A1 WO 2015105290A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- skin
- solvate
- acceptable salt
- lotion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 229940106189 ceramide Drugs 0.000 title claims description 51
- -1 ceramide compound Chemical class 0.000 title claims description 44
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 title claims description 41
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 title claims description 41
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 title claims description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 239000012453 solvate Substances 0.000 claims abstract description 25
- 230000008591 skin barrier function Effects 0.000 claims abstract description 20
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract 3
- 239000006210 lotion Substances 0.000 claims description 20
- 150000001783 ceramides Chemical class 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 201000002661 Spondylitis Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 208000010217 blepharitis Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 239000008269 hand cream Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000028185 Angioedema Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010024434 Lichen sclerosus Diseases 0.000 claims 1
- 241001420836 Ophthalmitis Species 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000010403 panophthalmitis Diseases 0.000 claims 1
- 208000017983 photosensitivity disease Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 abstract description 7
- 229940048864 ceramide 1 Drugs 0.000 abstract description 7
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- 238000009472 formulation Methods 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 210000000434 stratum corneum Anatomy 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 229940093499 ethyl acetate Drugs 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- JLYFWSUJCSRPET-UHFFFAOYSA-N 10-hexadecanoyloxydecanoic acid Chemical compound C(CCCCCCCCCCCCCCC)(=O)OCCCCCCCCCC(=O)O JLYFWSUJCSRPET-UHFFFAOYSA-N 0.000 description 2
- UGAGPNKCDRTDHP-UHFFFAOYSA-N 16-hydroxyhexadecanoic acid Chemical compound OCCCCCCCCCCCCCCCC(O)=O UGAGPNKCDRTDHP-UHFFFAOYSA-N 0.000 description 2
- WBIZTLRVYQWHDK-UHFFFAOYSA-N 16-octanoyloxyhexadecanoic acid Chemical compound C(CCCCCCC)(=O)OCCCCCCCCCCCCCCCC(=O)O WBIZTLRVYQWHDK-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000020104 CEBALID syndrome Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010062639 Herpes dermatitis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000013538 functional additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- OOCSVLHOTKHEFZ-UHFFFAOYSA-N icosanamide Chemical compound CCCCCCCCCCCCCCCCCCCC(N)=O OOCSVLHOTKHEFZ-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- MNBKLUUYKPBKDU-BBECNAHFSA-N palmitoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MNBKLUUYKPBKDU-BBECNAHFSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CQUHXTZAMFZWNZ-UHFFFAOYSA-N 10-hydroxydecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCO CQUHXTZAMFZWNZ-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GCSHATLPTFNXOS-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO.OCCCCCCCCCCO GCSHATLPTFNXOS-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- REEZZSHJLXOIHL-UHFFFAOYSA-N octanoyl chloride Chemical compound CCCCCCCC(Cl)=O REEZZSHJLXOIHL-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
Definitions
- the present invention is a novel analogue with structural characteristics similar to that of natural ceramides.
- the stratum corneum is the most important structure of skin barrier function and is composed of corneocytes and SC intercellular lipids. It prevents excessive loss and prevents external allergens and harmful substances from penetrating the skin.
- the keratinocytes of the stratum corneum have various lipids such as spingolipids, phospholipids, cholesterol sulfate, and neutral lipids, and these lipids are present between the keratinocytes. It acts as a skin barrier to prevent evaporation of moisture in the skin and to protect the skin from external irritation or contamination.
- Ceramides which are a type of skin in question, are N-acylated sphingoids. As a compound, involved in cell death
- the ceramide synthesis in cells is a signaling agent.
- the ceramide synthesis in cells is a signaling agent.
- ceramide In the structure of ceramide, long-chain fatty acid (C16) or higher forms the basic structure, and the most common form of ceramide 1 is omega-hydroxy fatty acid and unsaturated.
- a smooth supply of long chain omega-hydroxy fatty acids is essential for ceramide synthesis.
- synthetic ceramide is a commercially available synthetic synthetic ceramide produced through fermentation process and synthesis process using yeast. Ceramide is composed of ceramide III and ceramide IV. These synthetic ceramides are priced at a high price of 1.5 to 2 million won / kg. It is limited to use as a cosmetic material.
- the ceramide III and ceramide IV not only have functional limits in the formation of skin barrier, but also have the problem of high solubility in stone lumps and are difficult to use at high concentrations. .
- omega-hydroxy fatty acid was used to synthesize novel pseudoceramide compounds with structural properties similar to those of natural ceramide 1.
- the present invention has been applied to the present invention, confirming that it has an effect of improving skin barrier function as well as promoting the differentiation of keratinocytes.
- the object of the present invention is to provide a novel, similar ceramide compound, a pharmaceutically acceptable salt or solvate thereof, which has a structural characteristic similar to that of natural ceramide 1, which has an excellent effect on improving skin barrier function.
- the present invention is to provide a pharmaceutical composition having an effect on improving skin barrier function and improving inflammatory skin disease, containing a novel similar ceramide compound, a pharmaceutically acceptable salt or solvate thereof as an active ingredient.
- Another object of the present invention is the novel similar ceramide compound
- the present invention provides a pseudoceramide compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt or solvate thereof.
- ⁇ is hydroxyalkyl of hydrogen or carbon number (C1 C10)
- R 2 is, independently, linear or branched alkyl of carbon number (C 4 to C 20), [17] m and n are each independently 1 to 18 integers.]
- the compound is ⁇ hydrogen or C1 -C4 hydroxyalkyl, and 3 ⁇ 4 each independently can be a linear or branched alkyl of C2 -C17.
- the similar ceramide compound represented by Chemical Formula 1 may be an integer of 5 to 15 independently of m and n, respectively.
- the pseudoceramide compound according to an embodiment of the present invention may be a pseudoceramide compound represented by the following structure.
- the present invention includes a pharmaceutical composition having an improvement in skin barrier function and an improvement in inflammatory skin disease, containing a similar ceramide compound represented by the above Chemical Formula 1, and a pharmaceutically acceptable salt or solvate thereof as an active ingredient. .
- the inflammatory skin disease includes atopic dermatitis, allergic rhinitis, psoriasis, contact dermatitis, eczema dermatitis, ray dermatitis, seborrheic dermatitis, herpes dermatitis, squamous line, scleroderma, Necrotizing pyoderma, pemphigus, bullous epidermis, Vascular edema, blepharitis, allergic conjunctivitis, degenerative or inflammatory ocular inflammation, arthritis, rheumatoid arthritis, spondylitis, systemic sclerosis, skin myositis, polymyositis, inflammatory myopathy, acquired immunodeficiency syndrome, leprosy, tricuspid syndrome, inflammatory bowel disease or stress It may be a disease.
- the composition may contain from 0.005 to 20% by weight of a similar ceramide compound, a pharmaceutically acceptable salt or a solvate thereof, based on the total weight.
- the present invention is a pseudo ceramide compound represented by the formula (1),
- composition having skin barrier improvement and skin moisturizing effect which contains a pharmaceutically acceptable salt or solvate as an active ingredient.
- the composition includes a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizer, a nutrition lotion, a massage cream, a nutrition cream, a moisture cream, a hand cream, a foundation, It may be an essence, nutrition essence, pack, soap, cleansing product, cleansing lotion, cleansing cream, body lotion or body cleanser.
- the composition may contain 0.005 to 20% by weight of a similar ceramide compound, a pharmaceutically acceptable salt or a solvate thereof, based on the total weight.
- the present invention provides a novel analogous ceramide compound having structural properties similar to that of natural ceramide 1 represented by Chemical Formula 1, and the compound of Chemical Formula 1 according to the present invention, and a pharmaceutically acceptable salt or solvent thereof It is effective in improving barrier function and treating and preventing inflammatory skin diseases. It is useful as a pharmaceutical or cosmetic composition.
- 1 is a TEER for evaluating artificial skin integrity according to an embodiment of the present invention.
- FIG. 2 shows the results of immunohistochemical staining of the expression pattern of the differentiation marker protein, filaggrin, for the purpose of measuring the effect of promoting partial skin fragmentation according to an embodiment of the present invention.
- Salts or complexes that possess the desired biological activity of the compound and that exhibit minimal or no undesirable toxic effects are referred to.
- the present invention provides a pseudoceramide compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt or solvate thereof.
- R t is hydrogen or carbon atoms (C1-C10) hydroxyalkyl
- R 2 is, independently, linear or branched alkyl, of carbon number (C 4 -C 20),
- n and n are each independently 1 to 18 integers.
- the similar ceramide compound represented by the following Chemical Formula 1 is not limited thereto, but in terms of forming a stable lamellar layer, preferably, a hydrogen of ⁇ dihydrogen or carbon number (C1-C4) Roxyalkyl, R 2 may each independently be a similar ceramide compound which is a linear or branched alkyl of carbon number (C5-C17), but is not limited thereto, wherein m and n are not limited thereto. It may be a similar ceramide compound, more preferably 5 to 15 integers, in terms of maintaining the interlayer distance of the layers above lOnm, which is similar to the stratum corneum.
- Similar ceramide compounds, pharmaceutically acceptable salts or solvates of the present invention may be selected from similar ceramide compounds represented by the following structures, but not limited thereto.
- the quasi-ceramide derivative represented by Chemical Formula 1 according to the present invention is not particularly limited, but may be manufactured through an organic substance already known through the path of Formula 1 below.
- the present invention provides a pharmaceutical composition having an effect on improving skin barrier function and on improving inflammatory skin disease, containing an active ceramide compound, a pharmaceutically acceptable salt or a solvate thereof according to the present invention.
- ceramide compound may be in the form of a therapeutically active, non-toxic base or acid addition salt that the ceramide compound can form.
- the non-toxic base is sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, Iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, Suberrate, Sebacate, Fumarate, Maliate,
- Methanesulfonate propanesulfonate, naphthalene-1-sulfonate,
- naphthalene-2-sulfonate or mandelate include, but are not limited to, naphthalene-2-sulfonate or mandelate.
- the acid addition salt is caused by a pharmaceutically acceptable free acid.
- the acid addition salts formed may be, but are not limited to, inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid or aliphatic mono or dicarboxylate, phenyl-substituted
- Aromatic acids such as alkanoates, hydroxyalkanoates or alkanedioates, or aliphatic or aromatic sulfonic acids, or acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-lluenesulfonic acid, tartaric acid, It may be an organic acid such as fumaric acid.
- the solvent of the solvate is not particularly limited, but may be preferably a hydrate or an alcoholate.
- the inflammatory skin diseases include atopic dermatitis, allergic rhinitis, psoriasis, contact dermatitis, eczema dermatitis, ray dermatitis, seborrheic dermatitis, herpes dermatitis, flatulence, scleroderma, necrotic pyoderma, swelling, blistering epidermal detachment Vascular edema, blepharitis, allergic conjunctivitis, degenerative or inflammatory ocular inflammation, arthritis, rheumatoid arthritis, spondylitis, systemic sclerosis, dermatitis, polymyositis, inflammatory myopathy, acquired immunodeficiency syndrome, leprosy, trident syndrome, inflammatory bowel disease or stress It may be a temper.
- the present invention may include at least one compound of the present invention in a pharmaceutically acceptable carrier.
- compositions of the present invention are also conventional in the technical field to which the invention pertains.
- Pharmaceutically acceptable carriers may be included in the pharmaceutical composition of the present invention, depending on how readily available to the knowledgeable person.
- the pharmaceutically acceptable carriers in the pharmaceutical composition of the present invention are commonly used in the presentation of lactose and dextrose. , Sucrose, Solbi, Manni, Starch, Acacia Rubber, Calcium Phosphate, Alginate, Gelatin, Calcium Silicate, Microcrystalline Cellulose, Polyvinylpyrrolidone, Cellulose, Water, Syrup, Methyl Cellulose, Methyl Hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be, but are not limited to.
- the pharmaceutical compositions of the present invention include, but are not limited to, lubricants, wetting agents, sweeteners, flavoring agents, emulsifying agents, Suspensions or preservatives may be additionally included.
- the pharmaceutical composition of the present invention may be formulated into conventional formulations using pharmaceutically acceptable carriers and / or excipients in accordance with methods readily available to those with ordinary knowledge in the technical field to which the invention pertains. It may be manufactured in the form or prepared by incorporation into a large volume container. Conventional formulations include, for example, oral (tablets, capsules, powders), intraoral, sublingual, rectal, intravaginal, intranasal, topical or A parenteral (including intravenous, cavernous, intramuscular, subcutaneous or intratracheal) dosage form.
- a compound according to the present invention may be in the form of a tablet containing starch or lactose, or a capsule containing sole or excipients.
- Liquid formulations include suspending agents (e.g., methyl salose, witepsol) and Either a semisynthetic glyceride or a mixture of apricot kernel oil and PEG-6 esters or a glyceride mixture such as a mixture of PEG-8 and caprylic / capric glycerides, together with pharmaceutically acceptable additives.
- suspending agents e.g., methyl salose, witepsol
- Either a semisynthetic glyceride or a mixture of apricot kernel oil and PEG-6 esters or a glyceride mixture such as a mixture of PEG-8 and caprylic / capric glycerides together with pharmaceutically acceptable additives.
- a sterile aqueous solution when injected parenterally, for example, intravenously, intracavernosally, intramuscularly, subcutaneously and intratracheally, wherein the solution is compatible with blood. It may also contain other substances (eg salts or monosaccharides, such as glucose) in order to have a good growth.
- substances eg salts or monosaccharides, such as glucose
- the pharmaceutical composition according to the embodiment of the present invention may be a transdermal absorption patch using tablets, pills, capsules, granules, powders, powders, solutions, patches, and microneedles It can be used in the form of injections.
- the compound of the present invention may be included in the pharmaceutical composition in an amount sufficient to produce a desired effect depending on the process or disease state.
- the pharmaceutical composition is similar to the total weight of ceramide compound,
- a pharmaceutically acceptable salt or solvate may contain from 0.005 to 20% by weight, preferably from 0.1 to 10% by weight, including but not limited to, a similar ceramide compound, a pharmaceutically acceptable salt thereof or a salt thereof. If the content of solvate is less than 0.005% by weight, the effect is insignificant. If it is more than 20% by weight, the stability is not only lowered but also the solubility in the formulation is not preferable.
- the present invention is similar to the ceramide compound represented by the following formula 1,
- the present invention provides a cosmetic composition having a skin barrier improvement function and a skin moisturizing effect containing a pharmaceutically acceptable salt or solvent as an active ingredient.
- the cosmetic composition is not particularly limited, but is preferably skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nourishing lotion, massage cream, nourishing cream, moisturizing cream, hand cream, foundation ,essence,
- the present invention compound is excellent in solubility and can be easily used in cosmetic compositions, and by containing it as an active ingredient, skin It can be used for barrier improvement and skin moisturizing.
- the formulation of the cosmetic composition is not particularly limited, but may preferably be a solution, emulsion, paste, cream, gel or surfactant-containing cleansing, in which case the formulation is a solvent or emulsion, as a solvent and solvent.
- Topical or emulsifying agents are used, preferably but not limited to water, ethanol, isopropane, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl
- the carrier component is animal fiber, plant fiber. Waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicon, bentonite, silica, talc or zinc oxide can be used.
- aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkyl amido Fatty acid esters may be used for betaine, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol.
- the cosmetic composition is based on the total weight of similar ceramide compounds,
- the content of the similar ceramide compound, pharmaceutically acceptable salt or solvate thereof is less than 0.005% by weight, the effect is insignificant.
- the stability is lowered and the solubility in the formulation is lowered. It can be undesirable.
- the cosmetic composition may further include functional additives or ingredients included in general cosmetic compositions, in addition to the similar ceramide compound, pharmaceutically acceptable salts or solvates thereof.
- the functional additives may include water-soluble vitamins, One or more ingredients may be selected from the group consisting of oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extracts, and the components of the general cosmetic composition include fats and oils, moisturizers, emollients, surfactants, organics or inorganics. It can be pigment, organic powder, ultraviolet absorbent, preservative, disinfectant, antioxidant, plant extract, pH adjuster, alcohol, pigment, flavoring, blood circulation accelerator, coolant, limiting agent or purified water. It can be used.
- reaction mixture After 15- (chlorocarbonyl) pentadecyl octanoate was dissolved in 12 ml of Toluene under nitrogen atmosphere, the reaction mixture was cooled to below 0 ° C by using an ice bath, and then 1.4 ml (10.04 mmol) of TEA was slowly added. After removing the reaction mixture, the reaction mixture was slowly heated to room temperature and stirred for 4 hours. The reaction mixture was added with purified water, added hydrochloric acid to pH 3, and further purified water and ethyl acetate were added to stir and settle to separate the organic layer. It was.
- a cosmetic composition (test formulation and control formulation) was prepared by the composition of Table 1 below.
- TEER trans-epithelial electrical resistance
- Example 1 As a result, it was confirmed that the test formulation containing Example 1 was effective in maintaining skin integrity of 12.3% or more as compared to the control formulation.
- the test formulation schedule containing Myristoyl / pal mitoyl oxostearamide / arachamide MEA (trade name: PC-9S) and Example 1 (approximately 500 mg) was coated with Myristoyl / palmitoyloxostearamide / aracamide M. After 24 hours, the expression of filaggrin, a differentiation marker protein, was observed by immunohistochemical staining.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 천연 세라마이드 1과 유사한 구조적 특성을 가지는 신규한 유사 세라마이드 화합물, 이의 약학적으로 허용되는 염 또는 용매화물을 유효성분으로 함유하는 약학 조성물 및 화장료 조성물에 관한 것으로,본 발명의 화합물을 유효성분으로 하는 조성물은 피부 장벽 기능 개선 효과가 뛰어나 염증성 피부 질환의 개선 효과를 가지며, 피부 장벽 개선 기능과 피부 보습강화 효과가 우수하다.
Description
명세서
발명의명칭:신규한유사세라마이드화합물，이를포함하는약학 조성물및화장료조성물
기술분야
[1] 본발명은천연세라마이드와유사한구조적특성을가지는신규한유사
세라마이드화합물및이의용도에관한것으로,보다상세하게는천연
세라마이드 1과유사한구조적인특성을가지는신규한유사세라마이드화합물 및이회약학조성물및화장료조성물에관한것이다.
배경기술
[2] 피부각질층 (stratum corneum： SC)은피부장벽기능의가장증요한구조로서 각질세포 (corneocytes)와각질세포간지질 (SC intercellular lipid)로이루어져 있다.각질세포간지질의다중층상구조는수분의과도한유실을방지하고, 외부의알레르겐이나유해물질이피부로침투하는것을억제하는역할을한다. 피부각질층의각질세포간에는스핑고지질 (sphingolipids),인지질 (phospholipids), 콜레스테를황산염 (cholesterol sulfate),중성지질 (neutral lipids)등다양한종류의 지질이존재하고，이러한지질들은각질세포사이에존재하여피부속수분의 증발을방지하고,외부자극이나오염으로부터피부를보호하는피부장벽의 기능을한다.피부에존재하는지질의한종류인세라마이드는 N-아실레이티드 스핑고이드 (N-acylated sphingoid)화합물로서세포사멸과관여되는
신호전달물질이다.세포내의세라마이드합성은세린 (serin)과
팔미토일-코엔자임 A(palmitoyl-CoA)두분자의복잡한생합성경로를통해 이루어진다.인간피부각질층에는현재까지총 11종의세라마이드가존재하는 것으로보고되어 있으며，특히세라마이드 1이피부장벽기능에가장중요한 역할을한다고보고되어 있다.인간각질층내세라마이드 (Human SC
ceramide)의구조를살펴보면 C16이상의긴사슬지방산 (long chain fatty acid)이 기본구조를이루고있고，특히가장많이존재하는세라마이드 1형태는 오메가 -하이드록시지방산 (omega-hydroxy fatty acid)과불포화
지방산 (unsaturated fatty acid)의결합으로형성된다.따라서기능성유사
세라마이드합성을위해서는긴사슬오메가 -하이드록시지방산 (long chain omega-hydroxy fatty acid)의원활한공급이필수적이라할수있다.
[3] 현재사용되고있는천연세라마이드는주로동물의신경조직 (뇌，척수
등)에서추출하여사용하며,광우병 (BSE)등의안전성에대한우려로인하여 화장품원료로서는사용이불가능하다.또한합성세라마이드는효모를이용한 발효공정과합성공정을거쳐생산되는세라마이드로현재상업화된합성 세라마이드는세라마이드 3(ceramide III)와세라마이드 4(ceramide IV)가 존재한다.이러한합성세라마이드는 150~200만원 /kg의고가의가격으로인하여
화장품소재로서사용하기에한계를가지고있다.
[4] 또한상기세라마이드 3(ceramide III)와세라마이드 4(ceramide IV)는피부장벽 형성에있어서기능적인한계를갖고있을뿐만아니라용해성이매우낮아제형 내석출둥의문제점이있어고농도로사용하는것이어렵다.
[5] 일반적인보습제에비하여세라마이드계열원료를포함한생리학적지질 복합물 (physiologic lipid mixture)은손상된피부장벽기능의회복을 진하는 것으로보고된바있으며，특히아토피피부염환자의증상개선에중간이상의 외용스테로이드제제와유사한효과를나타낸다는임상시험결과가발표된 바도있다.이러한장점에도불구하고,유사세라마이드의경우고가의가격과 낮은용해도로인하여다양한제형에도입하기어려운단점을지니고있다.
[6] 또한최근피부장벽기능에대한연구가집중되면서，세라마이드또는유사 세라마이드를이용한피부장벽개선용보습제개발이활발히이루어지고 있으나，현재까지개발되어진유사세라마이드는대부분세라마이드 3의구조를 기본으로개발되어졌다 (한국등록특허공보제 10-0570553호).
[7] 이에본발명자들은긴사슬오메가 -하이드록시지방산 (long chain
omega-hydroxy fatty acid)을이용하여천연세라마이드 1과유사한구조적인 특성을가지는신규한유사세라마이드화합물을합성하였으며,이를
이용함으로써피부장벽기능개선효과뿐아니라각질형성세포의분화를 촉진하는효과가있음을확인하여，본발명을출원하기에이르렀다.
발명의상세한설명
기술적과제
[8] 본발명의목적은피부장벽기능개선효과가뛰어난천연세라마이드 1과 유사한구조적인특성을가지는신규한유사세라마이드화합물，이의 약학적으로허용되는염또는용매화물을제공하는것이다.
[9] 본발명은신규한유사세라마이드화합물，이의약학적으로허용되는염또는 용매화물을유효성분으로함유하는피부장벽기능개선과염증성피부질환 개선효과를가지는약학조성물을제공하는것이다.
[10] 또한본발명의또다른목적은신규한유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을유효성분으로함유하는피부장벽 개선기능과피부보습강화효과를가지는화장료조성물을제공하는것이다. 과제해결수단
[11] 본발명은하기화학식 1로표시되는유사세라마이드화합물,이의약학적으로 허용되는염또는용매화물을제공한다.
[12] [화학식 1]
[14] [상기화학식 1에서，
[15] ^은수소또는탄소수 (C1 C10)의하이드록시알킬이고，
[16] R2는각각독립적으로탄소수 (C4~C20)의선형또는분지형알킬이고， [17] m및 n은각각독립적으로 1내지 18의정수이다.]
[18] 본발명의일실시예에따른상기화학식 1로표시되는유사세라마이드
화합물은 ^은수소또는탄소수 (C1-C4)의하이드록시알킬이고, ¾는각각 독립적으로탄소수 (C5-C17)의선형또는분지형알킬일수있다.
[19] 또한，본발명의일실시예에따른상기화학식 1로표시되는유사세라마이드 화합물은상기 m및 n은각각독립적으로 5내지 15의정수일수있다.
[20] 본발명의 일실시예에따른유사세라마이드화합물은하기구조로표시되는 유사세라마이드화합물일수있다.
[22] 또한본발명은상기화학식 1로표시되는유사세라마이드화합물，이의 약학적으로허용되는염또는용매화물을유효성분으로함유하는피부장벽 기능개선과염증성피부질환개선효과를가지는약학조성물을포함한다.
[23] 본발명의일실시예에따른상기염증성피부질환은아토피피부염，알레르 7 비염,건선，접촉성피부염，습진성피부염，광선피부염，지루피부염，포진성 피부염，편평태선，경화태선，괴저성농피증，천포창,수포성표피박리증，
맥관부종，안검염，알러지성결막염，퇴행성또는염증성안구염，관절염， 류마티스관절염,척추염，전신성경화증，피부근염，다발성근염,염증성근병변, 후천성면역결핍증，나병，세자리증후군,염증성창자병또는스트레스성 질환일수있다.
[24] 본발명의일실시예에따른상기조성물은총중량에대하여유사세라마이드 화합물，이의약학적으로허용되는염또는용매화물을 0.005내지 20중량 %로 함유될수있다.
[25] 또한본발명은상기화학식 1로표시되는유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을유효성분으로함유하는피부장벽 개선기능과피부보습강화효과를가지는화장료조성물을포함한다.
[26] 본발명의일실시예에따른상기조성물은스킨로션，스킨소프너，스킨토너， 아스트린젠트，로션，밀크로션，모이스쳐로션，영양로션,맛사지크림，영양크림， 모이스처크림,핸드크림,파운데이션,에센스,영양에센스，팩,비누，클렌징품， 클렌징로션，클렌징크림，바디로션또는바디클린저제형일수있다.
[27] 본발명의일실시예에따른상기조성물은총중량에대하여유사세라마이드 화합물,이의약학적으로허용되는염또는용매화물을 0.005내지 20증량 %로 함유될수있다.
발명의효과
[28] 본발명은화학식 1로표시되는천연세라마이드 1과유사한구조적특성을 가지는신규한유사세라마이드화합물을제공하며,본발명에따른화학식 1의 화합물，이의약학적으로허용되는염또는용매화물은피부장벽기능개선 효과가뛰어나염증성피부질환의치료및예방이가능하여，이는의약품이나 화장품조성물로서유용하다.
도면의간단한설명
[29] 도 1은본발명의실시예에따른인공피부완전도평가를위해 TEER
(transepithelial electrial resistance)를즉정한결과이다.
[30] 도 2는본발명의실시예에따른인공피부분화촉진효과측정을위해분화 지표단백질인필라그린 (filaggrin)의발현양상을면역조직화학염색으로관찰한 결과이다.
발명의실시를위한형태
[31] 본발명에따른유사세라마이드화합물및이의용도에대하여이하상술하나, 이때사용되는기술용어및과학용어에있어서다른정의가없다면,이발명이 속하는기술분야에서통상의지식을가진자가통상적으로이해하고있는 의미를가지며，하기의설명에서본발명의요지를불필요하게흐릴수있는 공지기능및구성에대한설명은생략한다.
[32] 본명세서에서사용되는용어를하기와같이정의한다.
[33] "인공피부완전도 (integrity)평가"는인공피부의전기적저항성을측정하여
피부장벽의개선정도를평가하는방법을의미한다.
[34] 또한 "약학적으로허용되는염"은상기본발명에따른유사세라마이드
화합물의요망되는생물학적활성을보유하고바람직하지않은독성효과를 최소한으로또는전혀나타내지않는염또는복합체를지칭한다.
[35] 본발명은하기화학식 1로표시되는유사세라마이드화합물，이의약학적으로 허용되는염또는용매화물을제공한다.
[38] [상기화학식 1에서，
[39] Rt은수소또는탄소수 (C1-C10)의하이드록시알킬이고,
[40] R2는각각독립적으로탄소수 (C4-C20)의선형또는분지형알킬이고，
[41] m및 n은각각독립적으로 1내지 18의정수이다.]
[42] 또한본발명에따른하기화학식 1로표시되는유사세라마이드화합물은이에 한정되는것은아니나,안정적인라멜라층을형성하기위한측면에서， 바람직하게는 ^이수소또는탄소수 (C1-C4)의하이드록시알킬이고, R2는각각 독립적으로탄소수 (C5-C17)의선형또는분지형알킬인유사세라마이드 화합물일수있으나，이에한정되지않는다.이때，상기 m및 n은이에한정되는 것은아니나,제형내라멜라층의층간거리를피부각질층과유사한 lOnm 이상으로유지하는측면에서，보다바람직하게는 5내지 15의정수인유사 세라마이드화합물일수있다.
[43] 본발명에따른유사세라마이드화합물，이의약제학적으로허용되는염또는 이꾀용매화물은하기구조로표시되는유사세라마이드화합물들로부터 선택될수있으나，이에한정이있는것은아니다.
[45] 본발명에따른화학식 1로표시되는유사세라마이드유도체는특별히 한정되지않으나，하기반웅식 1의경로를통하여이미알려져있는유기 통하여제조될수있다.
[46] [반웅식 1]
[47]
TEA
[49] 본발명에따른 "약제학적으로허용되는염 "은화학식 1로표시되는유사
세라마이드화합물이형성할수있는치료적으로활성인，비 -독성염기또는산 부가염의형태일수있다.
[50] 이때，상기비 -독성염기는설페이트，피로설페이트，바이설페이트，설파이트， 바이설파이트，니트레이트，포스페이트，모노하이드로겐포스페이트, 디하이드로겐포스페이트,메타포스페이트,피로포스페이트클로라이드, 브로마이드,아이오다이드,플루오라이드，아세테이트，프로피오네이트, 데카노에이트，카프릴레이트，아크릴레이트，포메이트，이소부티레이트， 카프레이트,헵타노에이트，프로피올레이트，옥살레이트，말로네이트， 석시네이트，수베레이트，세바케이트，푸마레이트，말리에이트,
부틴 디오에이트，핵산 -1,6-디오에이트,벤조에이트，클로로벤조에이트， 메틸벤조에이트，디니트로벤조에이트，하이드록시벤조에이트，
메톡시벤조에이트，프탈레이트，테레프탈레이트，벤젠설포네이트，
톨루엔설포네이트,클로로벤젠설포네이트,크실렌설포네이트,페닐아세테이트, 페닐프로피오네이트,페닐부티레이트，시트레이트，락테이트,
β-하이드록시부티레이트，글리콜레이트，말레이트，타트레이트，
메탄설포네이트，프로판설포네이트，나프탈렌 -1-설포네이트,
나프탈렌 -2-설포네이트또는만델레이트를포함하나，이에제한되는것은 아니다.
[51] 또한상기산부가염은약학적으로허용가능한유리산 (free acid)에의해
형성된산부가염일수있으며，이에한정되지는않으나바람직하게는，염산, 질산，인산，황산，브름화수소산，요드화수소산,아질산또는아인산과같은 무기산류이거나지방족모노또는디카르복실레이트，페닐-치환된
알카노에이트，하이드록시알카노에이트또는알칸디오에이트와같은방향족 산류이거나지방족또는방향족설폰산류이거나아세트산，안식향산，구연산， 젖산，말레인산,글루콘산，메탄설폰산， 4-를루엔설폰산，주석산，푸마르산과 같은유기산일수있다.
[52] 상기용매화물의용매는특별히제한되지는않으나，바람직하게는수화물또는 알콜화물일수있다.
[53] 또한본발명에관하여화합물의언급은특정의이성질체형태가특히
언급되지않는다면각각의그의가능한이성질체형태및이의흔합물인 화합물을포함하는것으로의도된다.
[54] 본발명에따른화합물은상이한다형형태로존재할수있다.비록상기식에서 명시적으로표시되지는않았지만，그러한형태는본발명의범위내에포함되는 것으로의도된다.
[55] 상기염증성피부질환은아토피피부염，알레르기비염，건선，접촉성피부염， 습진성피부염，광선피부염,지루피부염，포진성피부염，편평태선，경화태선， 괴저성농피증，천포창，수포성표피박리증，맥관부종，안검염,알러지성결막염, 퇴행성또는염증성안구염，관절염，류마티스관절염，척추염，전신성경화증, 피부근염，다발성근염,염증성근병변，후천성면역결핍증，나병,세자리증후군， 염증성창자병또는스트레스성질환일수있다.
[56] 본발명은약제학적으로허용가능한담체내에적어도하나이상의본발명의 화합물을포함할수있다.
[57] 또한본발명의약학조성물은당해발명이속하는기술분야에서통상의
지식을가진자가용이하게실시할수있는방법에따라,약제학적으로허용되는 담체를포함할수있다.본발명의약학조성물에포함되는약제학적으로 허용되는담체는제제시에통상적으로이용되는것으로서，락토스，덱스트로스， 수크로스,솔비를,만니를，전분，아카시아고무，인산칼슘，알기네이트，젤라틴, 규산칼슘,미세결정성셀를로스，폴리비닐피를리돈,셀를로스，물，시럽，메틸 셀를로스，메틸히드록시벤조에이트，프로필히드록시벤조에이트，활석， 스테아르산마그네슘또는미네랄오일일수있으나，이에한정되는것은 아니다.본발명의의약조성물은상기성분들이외에윤활제，습윤제，감미제， 향미제,유화계，현탁제또는보존제등을추가로포함할수있다.
[58] 본발명의약학조성물은당해발명이속하는기술분야에서통상의지식을 가진자가용이하게실시할수있는방법에따라，약제학적으로허용되는담체 및 /또는부형제를이용하여통상적인제제로제형화함으로써단위용량형태로 제조되거나또는다용량용기내에내입시켜제조될수있다.통상적인제형이라 함은예를들면경구 (정제，캡슐제，분말제)，구강내，혀밑，직장내，질내，비강 내，국소또는비경구 (정맥내，해면체내，근육내，피하또는관내를포함)투여 제형을일컫는다.예를들면，본발명에따른화합물은전분또는락토오즈를 함유하는정제형태이거나단독또는부형제를함유하는캡슐형태또는맛을 내거나색을띄게하는화학약품을함유하는현탁제형태로경구，구강내또는 혀밑투여될수있다.액체제제는현탁제 (예를들면,메틸샐를로오즈， 위텝솔 (witepsol)과같은반합성글리세라이드이거나행인유 (apricot kernel oil)와 PEG-6에스테르의혼합물이거나 PEG-8과카프릴릭 /카프릭글리세라이드의 흔합물과같은글리세라이드흔합물로써，약제학적으로허용가능한첨가제와 함께제조될수있다.또한,비경구적으로예를들면，정맥내，해면체내，근육내， 피하및관내를통하여주사되는경우무균의수용액형태로서사용하는것이 가장바람직하며，이때상기용액은혈액과의등장성을갖기위하여다른 물질들 (예를들면염 (salt)이거나만니를,글루코오스와같은단당류)를함유할 수도있다.
[59] 구체적으로본발명의일실시예에따른약학조성물은정제,필,캡슐,과립， 분말,산제,액제,패치제，마이크로니들을이용한경피흡수패치제또는
주사제의형태로사용될수있다.
[60] 본발명화합물은공정또는질환상태에따라요망되는효과를생성하기에 층분한양으로상기약학조성물내에포함될수있다.
[61] 상기약학조성물은총중량에대하여유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을 0.005내지 20중량 %，바람직하게는 0.1내지 10중량 %로함유할수있으나，이에한정되지는않는다.이때，유사 세라마이드화합물，이의약학적으로허용되는염또는이의용매화물의함량이 0.005중량 %미만일경우,효과가미미하고， 20중량 %초과일경우，안정성이 저하될뿐아니라제형에서의용해도가저하될수있어바람직하지않다.
[62] 또한본발명은하기화학식 1로표시되는유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을유효성분으로함유하는피부장벽 개선기능과피부보습강화효과를가지는화장료조성물을제공한다.
[63] 상기화장료조성물은특별히한정되지는않으나，바람직하게는스킨로션， 스킨소프너，스킨토너，아스트린젠트，로션,밀크로션，모이스쳐로션，영양로션, 맛사지크림,영양크림，모이스처크림，핸드크림，파운데이션，에센스，
영양에센스，팩，비누,클렌징품，클렌징로션，클렌징크림，바디로션또는 바디클린저제형일수있다.또한본발명화합물은용해성이우수하여화장료 조성물에용이하게사용될수있으며,이를유효성분으로함유함으로써, 피부장벽개선기능과피부보습용으로사용될수있다.
[64] 상기화장료조성물의제형은특별히한정되지는않으나，바람직하게는용액, 유탁액，페이스트,크림,겔또는계면활성제함유클렌징일수있다.이때， 제형이용액또는유탁액일경우，담체성분으로서용매，용매화제또는 유탁화제가이용되고，이에한정되지는않으나바람직하게는물，에탄올， 이소프로판을，에틸카보네이트,에틸아세테이트，벤질알코올,벤질
벤조에이트,프로필렌글리콜， 1,3-부틸글리콜오일，글리세를지방족에스테르, 폴리에틸렌글리콜또는소르비탄의지방산에스테를포함할수있다.또한 제형이페이스트，크림또는겔일경우,담체성분으로동물섬유，식물섬유,왁스， 파라핀，전분,트라칸트，샐롤로오스유도체，폴리에틸렌글리콜,실리콘， 벤토나이트,실리카,탈크또는산화아연이사용될수있으며，제형이
계면활성제함유클렌징인경우，담체성분으로서지방족알코올설페이트, 지방족알코올에테르설페이트，설포숙신산모노에스테르,이세티오네이트， 이미다졸리늄유도체，메틸타우레이트，사르코시네이트，지방산아미드에테르 설페이트，알킬아미도베타인，지방족알코을，지방산글리세리드，지방산 디에탄올아미드,식물성오일,리놀린유도체또는에록실화글리세를지방산 에스테르가사용될수있다.
[65] 상기화장료조성물은총중량에대하여유사세라마이드화합물,이의
약학적으로허용되는염또는이의용매화물을 0.005내지 20중량
바람직하게는 0.1내지 10증량 %로함유될수있으나，이에한정되지는않는다.
이때，유사세라마이드화합물,이의약학적으로허용되는염또는이의 용매화물의함량이 0.005증량 %미만일경우，효과가미미하고, 20증량 %초과일 경우，안정성이저하될뿐아니라제형에서의용해도가저하될수있어 바람직하지않다.
[66] 상기화장료조성물에는유사세라마이드화합물，이의약학적으로허용되는 염또는이의용매화물이외에기능성첨가물또는일반적인화장료조성물에 포함되는성분이추가로포함될수있다.이때,상기기능성첨가물로는수용성 비타민，유용성비타민,고분자펩티드，고분자다당，스핑고지질및해초 엑기스로이루어진군에서하나이상선택될수있고，상기일반적인화장료 조성물에포함되는성분은유지성분，보습제，에몰리엔트제，계면활성제，유기 또는무기안료,유기분체，자외선흡수제,방부제,살균제，산화방지제，식물 추출물， pH조정계，알콜，색소，향료，혈행촉진제，냉감제，제한 (制汗)제또는 정제수일수있으며，당업자가용이하게선택하여사용가능하다.
[67] 이하，본발명의이해를돕기위하여바람직한실시예를제시한다.그러나
하기의실시예는본발명을보다쉽게이해하기위하여제공되는것일뿐，하기 실시예는단지예시적인것이지본발명의범위를어떤식으로든제한하기위한 것은아니다.
[68]
[69] [실시예 1]유사세라마이드화합물 1의제조
유사세라마이
[71] [단계 1] 16-(octanoyloxy)hexadecanoic acid의제조
[72] 16-하이드록시핵사도데카노익산 (16-Hydroxyhexadecanoic acid) 2.0g
(7.34mmol)을클로로포름 60ml로 70°C에서용해후옥타노일
클로라이드 (Octanoyl chloride) 1.38ml (8.07mmol)를첨가하였다.상기혼합물을 4시간동안환류교반시켰다.반웅온도를실온으로낮추고상기흔합물에 정제수와디클로로메탄 (Dichloromethane)을첨가하고교반시켰다.이를 정치하여유기층을분리하고,유기층을브라인 (brine)용액으로 1회씻어주고， 무수황산마그네슘 (MgS04)로건조하고,여과하여여액을감압농축시켰다. 잔여물을컬럼크로마토그래프 (Dichloromethane: Methanol = 50:1)로분리하여흰 고체인화합물을얻었다. (2.93g, 7.34mmol, 100% yield).
[73]
[74] [단계 2] 16— (octanoyloxy)hexadecanoylketenedimer의제조
[75] 질소대기하에서 16-(octanoyloxy)hexadecanoic acid 2.0g (5.02mmol)을티오닐 클로라이드 (Thionyl chloride) 1.83ml (25.1mmol)에녹이고 2시간동안환류 교반시켰다.티오닐클로라이드 (Thionyl chloride)를진공으로제거하여만들어진
15- (chlorocarbonyl) pentadecyl octanoate을질소대기하에서 Toluene 12ml에 녹이고 Ice bath를이용하여반웅기온도를 0°C이하로냉각한뒤 TEA 1.4ml (10.04mmol)를천천히첨가하였다.첨가완료후 ice bath를제거하고반웅기 온도를서서히실온으로올린뒤 4시간교반시켰다.반응물에정제수를 첨가하고염산을첨가하여 pH3으로맞추고,정제수와에틸아세테이트 (Ethyl acetate)를추가로첨가하여교반시키고정치하여유기층을분리하였다.
유기층은브라인 (brine)용액으로 1회씻어주고，무수황산마그네슘 (MgS04)로 건조시켰다.이를여과하여여액을감압농축시키고，잔여물을컬럼
크로마토그래프 (Ethyl Acetate: Hexane = 1:30)로분리하여연노랑색고체인
16- (octanoyloxy)hexadecanoylketenedimer를얻었다. (270mg, 0.35mmol, 14% yield).
[76]
[77] [단계 3]유사세라마이드화합물 1의제조
[78] 16-(octanoyloxy)hexadecanoylketenedimer 270mg (0.35mmol)를에탄올 2.7ml에 녹이고，이용액에에탄올아민 (Ethanolamine) 0.043ml (0.7 lmmol)을첨가한뒤 60oC에서 4시간동안교반시켰다. TLC로반응을확인하고용매를감압농축하여 제거시켰다.농축물에에틸아세테이트 (Ethylacetate)와，정제수를첨가하고 염산을첨가하여 pH3으로맞추고,교반，정치하여유기층을분리시켰다.
유기층을무수황산마그네슴 (MgS04)로건조시키고，여과한여액을감압 농축시켰다.이의용매를완전히제거시키고，잔여물을컬럼
크로마토그래프 (Dichloromethane: Methanol = 40:1)로분리하여연노랑고체 화합물을얻었다. (186mg, 0.23mmol, 66% yield).
[79] Ή-NMR (600MHz, chloroform-dl): 6.74 (s, 1H), 4.05 (t, J = 7.2 Hz, 4H), 3.71 (t, J = 5.4 Hz , 2H), 3.43-3.39 (m, 3H), 2.58-2.52 (m, 3H), 2.29 (t, J = 7.8 Hz, 4H), 1.84-1.80 (m, 2H), 1.62-1.55 (m, 10H), 1.31-1.25 (m, 60H), 0.88 (t, J = 7.2 Hz, 6H).
[80] MS (ESI pos. ion) m/z: 822 (M+). Calc'd exact mass for C50H95NO7: 822.29.
[81]
[82] [실시예 2]유사세라마이드화합물 2의제조
[84] [단계 1] 10-hydroxydecyl palmitate의제조
[85] 1,10-데칸디올 (1,10— Decandiol) 20.0g (114.76mmol)을클로로포름 600ml로
650C에서용해시킨후팔미토일클로라이드 (Palmitoyl chloride) 17.5ml
(57.38mmol)를천천히첨가시켰다.상기흔합물을 12시간동안환류교반시키고, 반웅물의용매를 300ml정도남을때까지농축시킨다.반응하고남은
1,10-Decandi이는여과하여제거하고.이의여액을완전히농축시킨후잔여물을 컬럼크로마토그래프 (Dichloromethane: Methanol = 5으ᅳ1)로분리하여흰고체인 화합물을얻었다. (20.9g, 50.64mmol, 88% yield). _
[86]
[87] [단계 2] 10-(palmitoyloxy )decanoic acid의제조
[88] 클로로포름 629ml에피리디니움디클로메이트 (Pyridinium dichromate) 32.7g (151.9mmol)를첨가하고，상기현탁액에 10-하이드록시데실
팔미테이트 (10-hydroxydecyl palmitate) 20.9g (5().6rmnol)을클로로포름 209ml에 녹인용액을천천히첨가한뒤실온에서 24시간동안교반시켰다.반응물에 정제수를첨가하고교반하고정치하여유기층을분리한뒤무수황산
마그네슘 (MgS04)으로건조하고,여과한후여액을감압농축시켰다.잔여물을 컬럼크로마토그래프 (Dichloromethane: Methanol = 40:1)로분리하여흰색고체인 화합물을얻었다. (10.0g, 23.4mmol, 46% yield).
[89]
[90] [단계 3내지단계 4] 10-(palmitoyloxy)decanoyl ketenedimer의제조
[91] 질소대기하에서 10-(palmitoyloxy)decanoic acid 5.0g (11.7mmol)을티오닐
클로라이드 (Thionyl chloride) 4.3ml (58.6mmol)에녹이고 2시간동안환류 교반시켰다.티오닐클로라이드 (Thionyl chloride)를진공으로제거하여만들어진 9-(chlorocarbonyl)nonyl palmitate을질소대기하에서를루엔 30ml에녹이고 Ice bath를이용하여반웅기은도를 0oC이하로냉각한뒤트리에틸아민 (TEA) 3.3ml (23.4mmol)를천천히첨가시켰다.첨가완료후 ice bath를제거하고반웅기 、온도를서서히실온으로을린뒤밤새교반시켰다.반웅물에정제수를첨가하고 연산을첨가하여 pH3으로맞추고，정제수와에틸아세테이트 (Ethyl acetate)를 추가로첨가하여교반하고정치하여유기층을분리시켰다.유기층은
부라인 (brine)용액으로 1회씻어주고，무수황산마그네슘 (MgS04)으로 건조하고，여과하여여액을감압농축시켰다.잔여물을컬럼
크로마토그래프 (Ethyl Acetate: Hexane = 1 : 10)로분리하여연노랑색고체인 10-(palmitoyloxy)decanoyl ketenedimer를얻었다. (1.47g, 0.35mmol, 30.8% yield).
[92]
[93] [단계 5]유사세라마이드화합물 2의제조
[94] 10-(palmitoyloxy)decanoyl ketenedimer 1.34g (1.64mmol)를에탄을 13ml에
녹이고,이용액에에탄을아민 (Ethanolamine) 0.2ml (3.28mmol)을첨가한뒤 40oC에서밤새교반시켰다. TLC로반응을확인하고용매를감압농축하여 제거시켰다.농축물에에틸아세테이트 (Ethylacetate)와정제수를첨가하고 염산을첨가하여 pH3으로맞추고，교반，정치하여유기층을분리하였다.
유기층을무수황산마그네슴 (MgS04)로건조하고，여과한여액을감압농축하여 용매를완전히제거시켰다.잔여물을컬럼크로마토그래프 (Dichloromethane: Methanol = 40: 1)로분리하여연노랑고체화합물을얻었다. (810mg, 0.92mmol, 56% yield).
[95] Ή-NMR (600MHz, chloroform-dl) 6.69 (br s, 1H), 4.05 (m, 4H), 3.71 (t, J = 5.4 Hz , 2H), 3.44-3.38 (m, 3H), 2.56-2.49 (m, 3H), 2.29 (t, J = 7.2 Hz, 4H), 1.82- 1.80 (m, 2H), 1.62- 1.54 (m, 10H), 1.29-1.21 (m, 68H), 0.88 (t, J = 7.2 Hz, 6H).
[96] MS (ESI pos. ion) mix: 878 (M+). Calc'd exact mass for C54H103NO7: 878.40.
[97]
[98] [제조예 1]화장료조성물의제조
[99] 하기표 1의조성으로화장료조성물 (시험제형및대조제형)을제조하였다.
[100] 표 1
[Table 1]
[101]
[102] [시험예 1]인공피부완전도평가
[103] 인공피부 (Keraskin™ from MCTT, Seoul, Korea)에유사세라마이드인
미리스토일 /팔미토일옥소스테아라마이드 /아라카마이드엠이에이 (Myristoyl/pal mitoyl oxostearamide/arachamide MEA)(상품명： PC-9S)및실시예 1을함유하는 시험제형일정량을 (약 500mg)도포한후，도포전과 24시간후피부의
완전성 (integrity)을 TEER (trans-epithelial electrical resistance)측정을통하여 평가하였다.
[104] 대조제형은실시예 1을함유하지않는것을제외하고，상기와동일한방법으로 피부의완전성 (integrity)을 TEER (trans-epithelial electrical resistance)측정을 통하여평가하여，그각각의결과를도 1에나타내었다.
[105] 그결과，실시예 1을함유하는시험제형의경우대조제형에비해 12.3 %이상의 피부완전성 (integrity)을유지하는데효과를가짐을확인할수있었다.
[106]
[107] [시함예 2]인공피부분화촉진효과측정
[108] 인공피부 (Keraskin™ from MCTT, Seoul, Korea)에유사세라마이드인
미리스토일 /팔미토일옥소스테아라마이드 /아라카마이드엠이에이 (Myristoyl/pal mitoyl oxostearamide/arachamide MEA)(상품명： PC-9S)및실시예 1을함유하는 시험제형일정량을 (약 500mg)도포하고， 24시간후분화지표단백질인 필라그린 (filaggrin)의발현양상을면역조직화학염색으로관찰하였다.
[109] 대조제형은실시예 1을함유하지않는것을제외하고,상기와동일한방법으로 분화지표단백질인필라그린 (filaggrin)의발현양상을면역조직화학염색으로 관찰하여,그각각의결과를도 2에나타내었다.
[110] 그결과，실시예 1을함유하는실시제형의경우，대조제형에비해인공피부에서 분화지표단백질 (filaggrin)의발현이월등히증가되는것으로확인되어， 실시예 1을함유하는시험제형이피부의분화에효과가있음을확인할수 있었다.
Claims
[청구항 1] 하기화학식 1로표시되는유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물.
[화학식 1
[상기화학식 1에서，
1^은수소또는탄소수 (C1-C10)의하이드록시알킬이고， R2는각각독립적으로탄소수 (C4~C20)의선형또는분지형 알킬이고，
m및 n은각각독립적으로 1내지 18의정수이다.]
[청구항 2] 제 1항에있어서，
^은수소또는탄소수 (C1-C4)의하이드록시알킬이고，
R2는각각독립적으로탄소수 (C5~C17)의선형또는분지형 알킬인유사세라마이드화합물，이의약학적으로허용되는염 또는용매화물.
[청구항 3] 제 2항에있어서，
상기 m및 n은각각독립적으로 5내지 15의정수인유사 세라마이드화합물，이의약학적으로허용되는염또는용매화물.
[청구항 4] 제 2항에 있어서，
하기구조로표시되는유사세라마이드화합물，이의약학적으로 허용되는염또는용매화물.
[청구항 5] 하기화학식 1로표시되는유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을유효성분으로함유하는 피부장벽기능개선과염증성피부질환개선효과를가지는약학 조성물.
1]
[상기화학식 1에서，
1^은수소또는탄소수 (C1-C10)의하이드록시알킬이고,
R2는각각독립적으로탄소수 (C4-C20)의선형또는분지형 알킬이고,
m및 n은각각독립적으로 1내지 18의정수이다.]
[청구항 6] 제 5항에 있어서，
상기염증성피부질환은아토피피부염，알레르기비염，건선， 접촉성피부염，습진성피부염，광선피부염,지루피부염,포진성 피부염，편평태선，경화태선，괴저성농피증，천포창,수포성 표피박리증,맥관부종,안검염，알러지성결막염,퇴행성또는 염증성안구염,관절염，류마티스관절염,척추염，전신성경화증， 피부근염，다발성근염,염증성근병변，후천성면역결핍증，나병， 세자리증후군,염증성창자병또는스트레스성질환인약학
조성물.
[청구항 7] 제 5항에있어서,
상기조성물은총중량에대하여화학식 1로표시되는유사 세라마이드화합물，이의약학적으로허용되는염또는
용매화물을 0.005내지 20증량 %로함유하는약학조성물.
[청구항 8] 하기화학식 1로표시되는유사세라마이드화합물，이의
약학적으로허용되는염또는용매화물을유효성분으로함유하는 피부장벽개선기능과피부보습강화효과를가지는화장료 조성물.
[ 학식 1]
[상기화학식 1에서,
^은수소또는탄소수 (C1~C10)의하이드록시알킬이고, R2는각각독립적으로탄소수 (C4-C20)의선형또는분지형 알킬이고，
m및 n은각각독립적으로 1내지 18의정수이다.]
[청구항 9] 제 8항에있어서，
상기조성물은스킨로션,스킨소프너，스킨토너，아스트린젠트， 로션，밀크로션，모이스쳐로션，영양로션,맛사지크림，영양크림， 모이스처크림，핸드크림，파운데이션，에센스，영양에센스，팩， 비누，클렌징폼，클렌징로션，클렌징크림，바디로션또는 바디클린저제형인화장료조성물.
[청구항 10] 제 9항에 있어서，
상기조성물은총중량에대하여화학식 1로표시되는유사 세라마이드화합물，이의약학적으로허용되는염또는
용매화물을 0.005내지 20중량 %로함유하는화장료조성물.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/106,777 US9783489B2 (en) | 2014-01-13 | 2014-12-23 | Pseudo ceramide compound, and pharmaceutical composition and cosmetic composition comprising same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140004029A KR101545527B1 (ko) | 2014-01-13 | 2014-01-13 | 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 |
| KR10-2014-0004029 | 2014-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015105290A1 true WO2015105290A1 (ko) | 2015-07-16 |
Family
ID=53524086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2014/012726 WO2015105290A1 (ko) | 2014-01-13 | 2014-12-23 | 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US9783489B2 (ko) |
| KR (1) | KR101545527B1 (ko) |
| WO (1) | WO2015105290A1 (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101827469B1 (ko) | 2016-03-04 | 2018-02-09 | (주)네오팜 | 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000052640A (ko) * | 1996-11-11 | 2000-08-25 | 안용찬 | 비천연세라미드 관련화합물 및 이를 함유하는 피부외용제 |
| KR20010019411A (ko) * | 1999-08-27 | 2001-03-15 | 박병덕 | 유사세라마이드 및 천연오일을 함유하는 다중 라멜라에멀젼 형태의 모발화장료 |
| KR100693292B1 (ko) * | 2005-10-06 | 2007-03-13 | 주식회사 바이오랜드 | 신규한 유사 세라마이드 및 이를 함유하는 조성물 |
| US7344868B2 (en) * | 2003-06-03 | 2008-03-18 | Laurent Lassalle | Method for synthesizing ceramide-type compounds |
| KR20100001374A (ko) * | 2008-06-27 | 2010-01-06 | (주)이미인 | 천연 세라마이드의 특성을 가진 세라마이드 유사 화합물 |
| US20100173995A1 (en) * | 2009-01-06 | 2010-07-08 | Neopharm Co., Ltd. | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same |
| US20100286102A1 (en) * | 2004-11-22 | 2010-11-11 | Symrise Gmbh & Co. Kg | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage |
-
2014
- 2014-01-13 KR KR1020140004029A patent/KR101545527B1/ko active IP Right Grant
- 2014-12-23 US US15/106,777 patent/US9783489B2/en active Active
- 2014-12-23 WO PCT/KR2014/012726 patent/WO2015105290A1/ko active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000052640A (ko) * | 1996-11-11 | 2000-08-25 | 안용찬 | 비천연세라미드 관련화합물 및 이를 함유하는 피부외용제 |
| US6221371B1 (en) * | 1996-11-11 | 2001-04-24 | Aekyung Industrial Co., Inc. | Pseudoceramides, and dermatologic external preparations containing the same |
| KR20010019411A (ko) * | 1999-08-27 | 2001-03-15 | 박병덕 | 유사세라마이드 및 천연오일을 함유하는 다중 라멜라에멀젼 형태의 모발화장료 |
| US7344868B2 (en) * | 2003-06-03 | 2008-03-18 | Laurent Lassalle | Method for synthesizing ceramide-type compounds |
| US20100286102A1 (en) * | 2004-11-22 | 2010-11-11 | Symrise Gmbh & Co. Kg | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage |
| KR100693292B1 (ko) * | 2005-10-06 | 2007-03-13 | 주식회사 바이오랜드 | 신규한 유사 세라마이드 및 이를 함유하는 조성물 |
| KR20100001374A (ko) * | 2008-06-27 | 2010-01-06 | (주)이미인 | 천연 세라마이드의 특성을 가진 세라마이드 유사 화합물 |
| US20100173995A1 (en) * | 2009-01-06 | 2010-07-08 | Neopharm Co., Ltd. | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101545527B1 (ko) | 2015-08-19 |
| US9783489B2 (en) | 2017-10-10 |
| US20170036995A1 (en) | 2017-02-09 |
| KR20150084223A (ko) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2813488B1 (en) | Amphoteric ion-type basic amino acid derivative | |
| KR101851010B1 (ko) | 항염증 및 항균활성을 가지는 조성물 | |
| TW201431831A (zh) | 新穎的類神經醯胺化合物與製備該化合物之方法 | |
| KR20150025286A (ko) | 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물 | |
| KR101827469B1 (ko) | 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 | |
| KR101462474B1 (ko) | 질레우톤 크림 제형의 국소용 항염증 약학적 조성물 | |
| WO2015105290A1 (ko) | 신규한 유사 세라마이드 화합물, 이를 포함하는 약학 조성물 및 화장료 조성물 | |
| KR101826747B1 (ko) | 신규한 코지산 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 피부 미백용 조성물 | |
| JP2022538505A (ja) | ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用 | |
| KR20100078704A (ko) | 토탄 추출물을 포함하는 화장료 또는 약학적 조성물 | |
| KR100539965B1 (ko) | 신규한 유사 세라마이드를 포함하는 아토피 피부염 예방및 완화용 화장료 조성물 | |
| KR101461625B1 (ko) | 16-히드록시헥사데카노익 피토스핑고신을 유효성분으로 포함하는 피부장벽 손상의 개선 또는 치료, 또는 피부장벽 기능의 개선 또는 강화용 조성물 | |
| KR102342503B1 (ko) | 루테올린 및 아피게닌의 혼합물을 유효성분으로 함유하는 항가려움용 조성물 | |
| KR100570810B1 (ko) | 신규 세라마이드 유도체, 이의 제조방법 및 이의 용도 | |
| CN110621654B (zh) | Trpv1调节剂化合物 | |
| JP4067211B2 (ja) | 皮膚外用剤 | |
| KR101655256B1 (ko) | 진세노사이드 Rg3를 포함하는 가려움 완화용 피부 외용제 조성물 | |
| JP2018510167A (ja) | フィトスフィンゴシン誘導体及びこれを含む組成物 | |
| KR20160118642A (ko) | 태지유사지질복합체와 우엉씨 추출물을 함유하는 가려움 완화용 피부 외용제 조성물 | |
| KR102592150B1 (ko) | 살리실산 유도체를 포함하는 신규한 스핑고지질 및 이를 포함하는 조성물 | |
| KR20200042687A (ko) | 신규한 유사 세라마이드 화합물 및 이를 포함하는 피부 외용제 조성물 | |
| KR102611023B1 (ko) | 탈수소 아비에틱산을 포함하는 피부 장벽 강화용 또는 보습용 피부 외용제 조성물 | |
| JP5328254B2 (ja) | セラミド産生促進剤 | |
| KR101149781B1 (ko) | 비스３，５?디메톡시칼콘을 포함하는 피부노화억제제 조성물 | |
| EP4296259A1 (en) | Novel ceramide, preparation method therefor, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14878081 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15106777 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14878081 Country of ref document: EP Kind code of ref document: A1 |